O	0	1	A
O	2	7	phase
O	8	10	II
O	10	11	,
O	12	22	randomized
O	22	23	,
O	24	31	blinded
O	32	37	study
O	38	40	of
O	41	44	the
O	45	64	farnesyltransferase
O	65	74	inhibitor
B-intervention	75	85	tipifarnib
I-intervention	86	94	combined
I-intervention	95	99	with
I-intervention	100	109	letrozole
O	110	112	in
O	113	116	the
O	117	126	treatment
O	127	129	of
O	130	138	advanced
O	139	145	breast
O	146	152	cancer
O	153	158	after
O	159	171	antiestrogen
O	172	179	therapy
O	179	180	.

O	181	185	This
O	186	191	study
O	192	200	assessed
O	201	204	the
O	205	213	clinical
O	214	222	efficacy
O	223	225	of
O	226	229	the
O	230	249	farnesyltransferase
O	250	259	inhibitor
O	259	260	,
O	261	271	tipifarnib
O	271	272	,
O	273	281	combined
O	282	286	with
O	287	296	letrozole
O	297	299	in
O	300	308	patients
O	309	313	with
O	314	322	advanced
O	323	329	breast
O	330	336	cancer
O	337	340	and
O	341	348	disease
O	349	360	progression
O	361	370	following
O	371	383	antiestrogen
O	384	391	therapy
O	391	392	.

B-eligibility	393	407	Postmenopausal
I-eligibility	408	413	women
I-eligibility	414	418	with
I-eligibility	419	427	estrogen
I-eligibility	427	428	-
I-eligibility	428	436	receptor
I-eligibility	436	437	-
I-eligibility	437	445	positive
I-eligibility	446	454	advanced
I-eligibility	455	461	breast
I-eligibility	462	468	cancer
I-eligibility	469	473	that
I-eligibility	474	477	had
I-eligibility	478	488	progressed
I-eligibility	489	494	after
I-eligibility	495	504	tamoxifen
O	505	509	were
O	510	515	given
O	516	517	2
O	517	518	.
O	518	519	5
O	520	522	mg
O	523	532	letrozole
O	533	537	once
O	538	543	daily
O	544	547	and
O	548	552	were
O	553	561	randomly
O	562	570	assigned
O	571	572	(
O	572	573	2
O	573	574	:
O	574	575	1
O	575	576	)
O	577	579	to
O	580	590	tipifarnib
O	591	594	300
O	595	597	mg
O	598	599	(
O	599	601	TL
O	601	602	)
O	603	605	or
B-control	606	613	placebo
O	614	615	(
O	615	616	L
O	616	617	)
O	618	623	twice
O	624	629	daily
O	630	633	for
O	634	636	21
O	637	648	consecutive
O	649	653	days
O	654	656	in
O	657	659	28
O	659	660	-
O	660	663	day
O	664	670	cycles
O	670	671	.

O	672	675	The
O	676	683	primary
O	684	692	endpoint
O	693	696	was
B-outcome-Measure	697	706	objective
I-outcome-Measure	707	715	response
I-outcome-Measure	716	720	rate
O	720	721	.

O	722	724	Of
B-total-participants	725	728	120
O	729	737	patients
O	738	745	treated
O	746	750	with
O	751	753	TL
O	754	755	(
O	755	756	n
O	757	758	=
B-intervention-participants	759	761	80
O	761	762	)
O	763	765	or
O	766	767	L
O	768	769	(
O	769	770	n
O	771	772	=
B-control-participants	773	775	40
O	775	776	)
O	776	777	,
B-total-participants	778	781	113
O	782	786	were
O	787	796	evaluable
O	797	800	for
O	801	809	response
O	809	810	.

B-outcome	811	820	Objective
I-outcome	821	829	response
I-outcome	830	834	rate
O	835	838	was
B-iv-bin-percent	839	841	30
I-iv-bin-percent	841	842	%
O	843	844	(
O	844	846	95
O	846	847	%
O	848	850	CI
O	850	851	;
O	852	854	20
O	854	855	-
O	855	857	41
O	857	858	%
O	858	859	)
O	860	863	for
O	864	866	TL
O	867	870	and
B-cv-bin-percent	871	873	38
I-cv-bin-percent	873	874	%
O	875	876	(
O	876	878	95
O	878	879	%
O	880	882	CI
O	882	883	;
O	884	886	23
O	886	887	-
O	887	889	55
O	889	890	%
O	890	891	)
O	892	895	for
O	896	897	L
O	897	898	.

O	899	904	There
O	905	908	was
O	909	911	no
O	912	923	significant
O	924	934	difference
O	935	937	in
B-outcome	938	946	response
I-outcome	947	955	duration
O	955	956	,
B-outcome	957	961	time
I-outcome	962	964	to
I-outcome	965	972	disease
I-outcome	973	984	progression
O	985	987	or
B-outcome	988	996	survival
O	996	997	.

B-outcome	998	1006	Clinical
I-outcome	1007	1014	benefit
I-outcome	1015	1020	rates
I-outcome	1021	1025	were
B-iv-bin-percent	1026	1028	49
I-iv-bin-percent	1028	1029	%
O	1030	1031	(
O	1031	1033	TL
O	1033	1034	)
O	1035	1038	and
B-cv-bin-percent	1039	1041	62
I-cv-bin-percent	1041	1042	%
O	1043	1044	(
O	1044	1045	L
O	1045	1046	)
O	1046	1047	.

O	1048	1058	Tipifarnib
O	1059	1062	was
O	1063	1072	generally
O	1073	1077	well
O	1078	1087	tolerated
O	1087	1088	;
O	1089	1090	a
O	1091	1097	higher
O	1098	1107	incidence
O	1108	1110	of
B-outcome	1111	1115	drug
I-outcome	1115	1116	-
I-outcome	1116	1123	related
I-outcome	1124	1136	asymptomatic
I-outcome	1137	1142	grade
I-outcome	1143	1144	3
I-outcome	1144	1145	/
I-outcome	1145	1146	4
I-outcome	1147	1158	neutropenia
O	1159	1162	was
O	1163	1171	observed
O	1172	1175	for
O	1176	1178	TL
O	1179	1180	(
B-iv-bin-percent	1180	1182	18
I-iv-bin-percent	1182	1183	%
O	1183	1184	)
O	1185	1189	than
O	1190	1193	for
O	1194	1195	L
O	1196	1197	(
B-cv-bin-percent	1197	1198	0
I-cv-bin-percent	1198	1199	%
O	1199	1200	)
O	1200	1201	.

O	1202	1212	Tipifarnib
O	1213	1223	population
O	1224	1240	pharmacokinetics
O	1241	1245	were
O	1246	1253	similar
O	1254	1256	to
O	1257	1265	previous
O	1266	1273	studies
O	1273	1274	,
O	1275	1279	with
O	1280	1282	no
O	1283	1294	significant
O	1295	1305	difference
O	1306	1308	in
O	1309	1315	trough
O	1316	1325	letrozole
O	1326	1340	concentrations
O	1341	1348	between
O	1349	1352	the
O	1353	1355	TL
O	1356	1359	and
O	1360	1361	L
O	1362	1368	groups
O	1368	1369	.

O	1370	1376	Adding
O	1377	1387	tipifarnib
O	1388	1390	to
O	1391	1400	letrozole
O	1401	1404	did
O	1405	1408	not
O	1409	1416	improve
O	1417	1426	objective
O	1427	1435	response
O	1436	1440	rate
O	1441	1443	in
O	1444	1448	this
O	1449	1459	population
O	1460	1462	of
O	1463	1471	patients
O	1472	1476	with
O	1477	1485	advanced
O	1486	1492	breast
O	1493	1499	cancer
O	1499	1500	.
